Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
73 participants
INTERVENTIONAL
2011-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
NCT01011374
The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity
NCT02304068
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
NCT04988178
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
NCT04982484
Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
NCT00407355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
AMD-related information is not given to patients randomized to the control group.
No interventions assigned to this group
Video materials
Educational materials are presented in through a video (audio and visual)
Video
AMD-related information is presented as in the form of a video
Print materials
Educational materials are presented in the format of printed brochure (visual)
Printed materials
AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Printed materials
AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
Video
AMD-related information is presented as in the form of a video
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AMD patients requiring intravitreal injections
Exclusion Criteria
* Any contraindications to intravitreal injections, such as IOP elevations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wai-Ching Lam
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Toronto Western Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHN-110463AE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.